When it comes to CLL/SLL treatment, what’s the difference between BTK inhibitors and BCL-2 inhibitors? Understanding how these treatment approaches work and how they fit into the treatment…
BTK degrader BGB-16673 reduced tumor burden in 85% of patients from a high-risk, hard-to-treat group with relapsed / refractory CLL. Dr. Stephan Stilgenbauer from Ulm University and colleagues…
Although there exists no reliable government database about demand for cadavers, sources like National Geographic and The Economist have reported on data compiled from individual agencies about shortages…
An accumulation of fat in liver cells can lead to inflammation and cell death which can develop into nonalcoholic steatohepatitis (NASH). It can progress over many years into…
Each month we present you with the latest featured study from the research teams at JAMA, Journal of the American Medical Association. Check out the video for intriguing…
